AbCellera Biologics posted Q2 2026 revenue of USD 4.1 million, down 76.29% from a year earlier.
Net loss widened to USD 55.4 million, or USD 0.18 per share, from a USD 34.7 million loss a year earlier.
R&D expenses rose to USD 46 million from USD 39.2 million, while SG&A costs fell to USD 13.9 million from USD 22 million.
The company ended the quarter with over USD 565 million in cash and marketable securities; total available liquidity topped USD 675 million including USD 110 million in government funding.
Pipeline and partnerships
Phase 2 ABCL635 top-line data are expected in August 2026.
New T-cell engager deals with Jazz (USD 84 million upfront) and Vertex (USD 28 million upfront) add over USD 100 million.
ABCL•
